Neuronetics to Report First Quarter 2023 Financial and Operating Results and Host Conference Call

MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release first quarter 2023 financial and operating results prior to market open on Tuesday, May 9th, 2023. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/dkh33hi3. To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start.

About Neuronetics

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 5.3 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com.

Investor Contact:
Mike Vallie or Mark Klausner
ICR Westwicke
443-213-0499
ir@neuronetics.com

Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com

Staff

Recent Posts

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

-Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in third cohort, permitting escalation…

50 minutes ago

FendX Discusses CDC Recent Reports on the Rise of Antimicrobial Resistance

CDC reports antimicrobial resistance is an urgent global public health threat and, in the U.S.,…

3 hours ago

Fosun Wealth Holdings Strengthens Fintech Strategy as Finloop Becomes a Strategic Enterprise of OASES

HONG KONG, April 9, 2025 /PRNewswire/ -- Finloop Finance Technology Holding Limited ("Finloop"), an AI-driven…

3 hours ago

Major Cost Savings on Top Cancer Drugs with India-Approved Alternatives

Patients Can Save Thousands on Life-Saving Oncology Medications by Accessing Safe, Affordable Options says SaveRxCanada.to…

3 hours ago

VARON Expands Access to Oxygen Therapy–Breathing Easier, Living Stronger

NEW YORK, April 8, 2025 /PRNewswire/ -- VARON, a leading provider of respiratory solutions, is…

9 hours ago

WELL Health to Report Fourth Quarter and Year End 2024 Financial Results on April 14, 2025

VANCOUVER, BC, April 8, 2025 /PRNewswire/ - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ("WELL"…

9 hours ago